Podcast 5 Jan 2024 Gene editing in the microbiome could provide acne solution Eligo Bioscience is a gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, and in its crosshairs, initially, is moderate to severe acne… January 5, 2024 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2023 Calida Therapeutics launches to tackle thrombo-inflammatory disorders …in a broad range of indications, from cardiovascular diseases to the complications of autoimmune diseases. Its approach aims to “disrupt the molecular link between thrombosis and inflammation by preventing the… April 11, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 19 Sep 2017 Scottish Scientists Claim that the Genome Controls the Aging of the Brain …that their findings could shed light on the genes that control diseases. For example, symptoms of schizophrenia tend not to appear until early adulthood despite being present in the individual… September 19, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2016 Find Out what’s Hot in the Latin American Biotech scene …and the human placenta. Stem cells are traditionally harvested from bone marrow, but from its comparatively noninvasive source, C4C hopes to develop treatments for degenerative diseases including those affecting the… November 17, 2016 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Best in Biotech 5 Mar 2025 Seven biotech companies keeping Taiwan dynamic in 2025 …solid tumors Senhwa Biosciences is a clinical-stage biotech company based in Taipei, Taiwan developing first-in-class therapeutics for oncology, rare diseases, and infectious diseases. The company specializes in next-generation DNA damage… March 5, 2025 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Interview 6 Mar 2017 How did this Biotech seal a €1B Deal with AstraZeneca? The CEO Explains We talked to the CEO of Bicycle Therapeutics, Kevin Lee, about how his company’s technology could cure not just cancer but also a raft of other diseases. Bicycle Therapeutics made… March 6, 2017 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2023 Pancreatic cancer microbiome discovery holds treatment hope …neurological diseases such as Alzheimer’s disease and Parkinson’s disease. “Our bacteriophage-based new drug is undoubtedly a ‘first-in-concept’ drug that can effectively control various immune-related diseases. Therefore, we will continue to… May 30, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Apr 2017 Swiss Pharma Clears €37M Funding to Develop a New Class of Antibiotics …specific class of so called ‘macrocyclic drugs‘, which are chemically defined by a ring structure. The company’s pipeline is covering a broad range of diseases such as leukemia, infectious diseases… April 12, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2022 Treatment for adults with chronic skin condition approved by FDA …a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type… September 29, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
In Depth 19 Apr 2023 How Vaccine Platforms Can Prepare Us for Future Pandemics …the risk of a zoonotic spillover — the transmission of diseases from animals to humans. With more than five new infectious diseases emerging each year, there’s always the threat of… April 19, 2023 - 7 minutesmins - By Sachin Rawat Share WhatsApp Twitter Linkedin Email
News and Trends 13 Dec 2016 European Pharma closes 2016 by launching new Biotech Startups …regenerative medicine for diseases affecting the nervous and cardiovascular systems. Given that CNS diseases are marked by neuronal degeneration and CV diseases by muscular degeneration, regenerative medicine seems like the… December 13, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
More News! 19 Jul 2019 Mallinckrodt Teams up with UK RNAi Biotech in Deal Worth up to €553M The UK-based biotech Silence Therapeutics has signed a deal worth up to €553M ($693M) with the UK pharma company Mallinckrodt to develop RNA interference (RNAi) therapies for autoimmune diseases. Mallinckrodt… July 19, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email